Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 31, No 15_suppl (May 20 Supplement), 2013: 1521
April Ann Nicole Rose, Christine Elser and Pamela Jean Goodwin
Faculty of Medicine, McGill University, Montreal, QC, Canada; Princess Margaret Hospital, Toronto, ON, Canada; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background: Vitamin D (VitD) is a circulating hormone known to regulate gene transcription in breast cancer (BC) cells. The association between VitD and BC risk has been extensively studied. Until recently, however, the role of VitD in BC progression and its association with clinical outcomes among BC patients was poorly understood. To assess these new developments, a systematic review and meta-analysis was performed.
Methods: A systematic review and meta-analysis by searching MEDLINE (1982 – 2012), ASCO, and SABCS for abstracts (2009 – 2012), with the following keywords: "breast cancer" and "prognosis" or "survival", and "vitamin D" or "calcitriol." Abstracts were scrutinized for reports correlating serum VitD levels with breast cancer clinical outcomes, including: disease-free survival (DFS) and overall survival (OS). Studies were included if serum VitD samples were taken shortly after diagnosis and survival data were reported. Meta-analyses were performed using an inverse-variance weighted fixed-effects model.
Results: We identified 7 studies reporting correlative data between serum VitD levels and BC survival. These data included 4,885 patients evaluated for DFS and 3858 patients evaluated for OS.
VitD-deficiency was defined as <30ng/mL, <20ng/mL, and <14ng/mL in 3, 3, and 1 studies, respectively, and was identified in an average of 48.1% of patients (range: 17.9-87.8%).
VitD deficiency was associated with a pooled hazard ratio (HR) of 2.13 (CI: 1.64 - 2.78) and 1.76 (CI: 1.35 - 2.30) for DFS and OS, respectively.
Conclusions: To our knowledge, this is the first report of a meta-analysis of the relationship between serum VitD and BC prognosis. The prevalence of VitD-deficiency varied widely across studies and may reflect differences in geographic location, race, and rates of supplementation across patient populations. These findings support the hypothesis that VitD-deficient breast cancer patients have poorer clinical outcomes than VitD sufficient patients; but do not establish whether this relationship is causative. Further studies are warranted to investigate the possible protective effects of VitD supplementation on survival among VitD-deficient BC patients.
Abstract presentation from the 2013 ASCO Annual Meeting
- Breast Cancer and Vitamin D: Dr Garland - video June 2013
- 6X less Breast Cancer if have even minimal vitamin D – July 2013
- Vitamin D Might Be Able to Slash Your Breast Cancer Risk by 90 Percent - Baggerly, Mercola: May 2013
- All items in Cancer - Breast
- Overview Breast Cancer and Vitamin D
Breast Cancer survival 2X more likely if vitamin D sufficient – meta-analysis May 2013
- Deaths from many types of Cancer associated with low vitamin D- review of meta-analyses Sept 2020
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Death due to breast cancer reduced 40 percent if high vitamin D – meta-analysis April 2014
- More survive Breast Cancer if more vitamin D – 2X fewer deaths with just 30 ng -meta-analysis March 2014
- Colorectal and Breast Cancer – Vitamin D is associated with fewer deaths – meta-analysis Feb 2014
- Breast Cancer survival 2X more likely if vitamin D sufficient – meta-analysis May 2013
3748 visitors, last modified 24 Feb, 2019,